ES2944446T3 - Uso de la modulación de H3K9me3 para potenciar la función cognitiva - Google Patents

Uso de la modulación de H3K9me3 para potenciar la función cognitiva Download PDF

Info

Publication number
ES2944446T3
ES2944446T3 ES20172824T ES20172824T ES2944446T3 ES 2944446 T3 ES2944446 T3 ES 2944446T3 ES 20172824 T ES20172824 T ES 20172824T ES 20172824 T ES20172824 T ES 20172824T ES 2944446 T3 ES2944446 T3 ES 2944446T3
Authority
ES
Spain
Prior art keywords
composition
substituted
etp69
unsubstituted
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20172824T
Other languages
English (en)
Spanish (es)
Inventor
Carl Cotman
Larry Overman
Shikha Snigdha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2944446T3 publication Critical patent/ES2944446T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Networks Using Active Elements (AREA)
  • Amplifiers (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
ES20172824T 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva Active ES2944446T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562172690P 2015-06-08 2015-06-08

Publications (1)

Publication Number Publication Date
ES2944446T3 true ES2944446T3 (es) 2023-06-21

Family

ID=57504356

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20172824T Active ES2944446T3 (es) 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva
ES16808065T Active ES2807878T3 (es) 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16808065T Active ES2807878T3 (es) 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva

Country Status (11)

Country Link
US (5) US10272093B2 (enExample)
EP (2) EP3733188B1 (enExample)
JP (1) JP6851081B2 (enExample)
KR (1) KR102776570B1 (enExample)
CN (1) CN107849061B (enExample)
AU (2) AU2016276172B2 (enExample)
CA (1) CA2988568A1 (enExample)
ES (2) ES2944446T3 (enExample)
IL (1) IL256055B (enExample)
MX (1) MX2017015909A (enExample)
WO (1) WO2016200690A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017015909A (es) * 2015-06-08 2018-05-07 Univ California Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva.
CN111032025A (zh) * 2017-06-20 2020-04-17 居里研究所 Suv39h1组蛋白甲基转移酶的抑制剂在癌症联合治疗中的用途
CN108434454B (zh) * 2018-03-16 2019-10-11 大连医科大学 Adar1在缓解认知功能障碍方面的应用
WO2020223475A1 (en) * 2019-05-02 2020-11-05 Board Of Regents, The University Of Texas System Methods and compositions involving tert activating therapies
US20240009203A1 (en) * 2020-08-03 2024-01-11 Cedars-Sinai Medical Center Compositions and methods for treating alzheimer's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534255B1 (en) * 2003-01-24 2009-05-19 Photothera, Inc Low level light therapy for enhancement of neurologic function
US20060019227A1 (en) 2004-07-22 2006-01-26 Hardwicke Susan B Methods for cognitive treatment
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP2026783A2 (en) 2006-06-09 2009-02-25 Wyeth a Corporation of the State of Delaware Method for enhancing cognitive function
JP2009084271A (ja) * 2007-09-07 2009-04-23 Toyama Univ 脳由来神経栄養因子の発現誘導剤および発現誘導方法
NZ593447A (en) * 2008-12-03 2012-12-21 Harvard College Inhibition of hdac2 to promote memory
WO2011109267A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
KR101235256B1 (ko) * 2010-09-13 2013-02-21 서울대학교산학협력단 miRNA를 타겟으로 한 신경퇴행성 질환 치료
EP2909214B1 (en) 2012-10-22 2020-07-22 City of Hope Etp derivatives
CA2909506C (en) * 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
CA3089881C (en) * 2013-11-26 2024-04-02 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss
MX2017015909A (es) * 2015-06-08 2018-05-07 Univ California Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva.

Also Published As

Publication number Publication date
EP3733188B1 (en) 2023-01-25
IL256055A (en) 2018-01-31
KR20180014432A (ko) 2018-02-08
US20230057592A1 (en) 2023-02-23
AU2016276172B2 (en) 2019-07-11
AU2016276172A1 (en) 2018-01-04
EP3733188A1 (en) 2020-11-04
EP3303347A4 (en) 2019-03-06
CN107849061B (zh) 2021-05-14
US20240374608A1 (en) 2024-11-14
US11311551B2 (en) 2022-04-26
WO2016200690A1 (en) 2016-12-15
MX2017015909A (es) 2018-05-07
EP3303347A1 (en) 2018-04-11
CA2988568A1 (en) 2016-12-15
AU2019246902A1 (en) 2019-10-31
US10849910B2 (en) 2020-12-01
US20180228808A1 (en) 2018-08-16
US20210106590A1 (en) 2021-04-15
CN107849061A (zh) 2018-03-27
IL256055B (en) 2022-06-01
US20190209577A1 (en) 2019-07-11
AU2019246902B2 (en) 2021-08-19
ES2807878T3 (es) 2021-02-24
EP3303347B1 (en) 2020-05-06
US10272093B2 (en) 2019-04-30
JP6851081B2 (ja) 2021-03-31
JP2018516940A (ja) 2018-06-28
KR102776570B1 (ko) 2025-03-04

Similar Documents

Publication Publication Date Title
Song et al. Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson’s diseases
ES2944446T3 (es) Uso de la modulación de H3K9me3 para potenciar la función cognitiva
Choi et al. Effect of exercise-induced neurogenesis on cognitive function deficit in a rat model of vascular dementia
Qiao et al. PI3K-AKT-GSK3β-CREB signaling pathway regulates anxiety-like behavior in rats following alcohol withdrawal
Bickford et al. Aging leads to altered microglial function that reduces brain resiliency increasing vulnerability to neurodegenerative diseases
Shelton et al. The effects of a novel inhibitor of tumor necrosis factor (TNF) alpha on prepulse inhibition and microglial activation in two distinct rodent models of schizophrenia
Sun et al. Ligustilide enhances hippocampal neural stem cells activation to restore cognitive function in the context of postoperative cognitive dysfunction
Ma et al. A novel phthalein component ameliorates neuroinflammation and cognitive dysfunction by suppressing the CXCL12/CXCR4 axis in rats with vascular dementia
Luo et al. Fluoxetine ameliorates cognitive impairments induced by chronic cerebral hypoperfusion via down-regulation of HCN2 surface expression in the hippocampal CA1 area in rats
Li et al. ISRIB facilitates post-spinal cord injury recovery through attenuation of neuronal apoptosis and modulation of neuroinflammation
HK40040355A (en) Use of h3k9me3 modulation for enhancing cognitive function
HK40040355B (en) Use of h3k9me3 modulation for enhancing cognitive function
Uehara et al. Apocynin-tandospirone derivatives demonstrate antioxidant properties in the animal model of schizophrenia
CN115429782B (zh) 乙酸盐在制备预防或治疗神经系统发育障碍药物中的应用
Vittalrao et al. Cognitive Enhancing Activities of Coenzyme Q10, Ramipril, and Vinpocetine Through Modulating Neuroinflammatory Response and Oxidative Damage Inflicted by Acute REM Sleep Deprivation in Rats
Kou et al. Uncoupling nNOS-PSD-95 in mPFC inhibits morphine priming-induced reinstatement after extinction training
Mithaiwala The Role of Oxidative Kynurenine Metabolism in Mediating Hippocampal Cognitive Deficits in a Mouse Model of Chronic Inflammation
Shelton The Effects of Two Novel Anti-Inflammatory Compounds on Prepulse Inhibition and Neural Microglia Cell Activation in a Rodent Model of Schizophrenia
Chao-Liang et al. Tongqiao Huoxue Decoction ameliorates learning and memory defects in rats with vascular dementia by up-regulating the Ca2+-CaMKII-CREB pathway
Zhao et al. Ganoderma lucidum spore powder modulates Bcl-2 and Bax expression in the hippocampus and cerebral cortex, and improves learning and memory in pentylenetetrazole-kindled rats**★
Abdulla Investigating neuroprotectants for the treatment of Chemotherapy-Induced Peripheral Neuropathy
Alfei Palloni et al. Learning experience determines the fate of fear memories after post-training manipulations
Chen et al. Sodium fluoride-induced cognitive impairment by suppressing synaptic protein expression and nerve cell development